In this module you will:
- Review the changing role of Medical Affairs and how it has become a strong strategic partner in product launch excellence
- Gain insights into the components of launch excellence
- Understand the value of a collaborative cross-functional launch team to support launch excellence
- Identify processes, systems, and tools to support launch excellence
- Implement mechanisms for monitoring launch progress and evaluating impact and value
- Utilize templates to support launch excellence planning
At the end of this on-demand course, you will have the opportunity to take an exam to test your competencies on this topic.
Learners who score 80% or above will receive a certificate of completion which you may download as a PDF.
|Pre-assessment Quiz||10 questions|
|What is Launch Excellence?||5 minutes|
|Medical Affairs Launch Excellence Evolution and Future Landscape||5 minutes|
|Medical Affairs Launch Excellence Teams||5 minutes|
|The Medical Affairs’ Launch Excellence Process||10 minutes|
|Medical Affairs Excellence Strategy: Your Brand Vision||5 minutes|
|New and Growing Visionary Role||5 minutes|
|Certification Exam||10 Questions|
Who Should Take This Course
You do not need any kind of programming, technical, or mathematical skills to take this course.
However, an awareness of the importance of Medical Strategy and Launch preparedness will be helpful as the course provides a deep dive into operationalizing Launch Excellence.
Please access this eLearning module by using your MAPS credentials to login to this course HERE.
There is no additional cost for MAPS members to take this course.
Not a MAPS member,
but wish to take the course?
Please enroll for this course.
The cost for this module is $175 USD
and may be paid via the Enroll button below
Payments can be made via credit card, debit card, or bank account via PayPal’s secure payment
The MAPS Medical Affairs Launch Excellence eLearning module was developed by harnessing the valuable experience and collective insights from senior medical affairs leaders across the industry, synthesizing the key processes into a comprehensive framework, and delivering it as a simple and effective learning platform that facilitates knowledge retention.
Ramin Farhood, PharmD, MBA
Vice President of Medical Affairs Practice, SSI Strategy
Dr. Farhood is a pharmacologist, an enthusiastic Sr. Medical Executive and entrepreneur with over 20 years in developing business-aligned and patient-centric medical strategies and translating these into proven tactical execution via strategic R&D, payer evidence generation, & establishing registries, KOL engagements, advocacy development and establishing Early Access Programs (EAP), influential publications, behavior changing education and medical messaging. He is a pragmatic leader with experience in building high-functioning medical team with a scalable model while driving excellence in operations in bringing novel therapies in rare disorders to the market. He has demonstrated success in start-ups, specialty pharmaceutics and large pharma and has leveraged his clinical and business in to effective solutions responsive to today’s dynamic healthcare and challenging access environment.
Lobna Salem, MD, MSc, MBA
Head of Medical Affairs, Developed Markets & JANZ
Dr. Salem is the Head of Medical Affairs, Developed Markets & JANZ, Viatris/Legal Entity. She has held difference cross-functional roles in medical affairs, clinical development, regulatory interactions and commercial functions. Previously as Chief Medical Officer at Pfizer, Lobna medically led multiple business development activities for Pfizer as well joint venture in multiple countries globally. She received multiple awards in recognition for her and her team’s efforts in improving patient outcome as well as recognized for driving innovation across Research and Development in Pfizer. Lobna is a hematologist by training; she received her Medical degree from Cairo University and MBA from Edinburgh business school UK and MSc from Hibernia Ireland.
Paul W. Tebbey, PhD, MBA
Vice-President, Medical Affairs Biosimilars
Dr. Paul W. Tebbey has 25 years of healthcare experience across the biotechnology and pharmaceutical sectors. Dr. Tebbey received a PhD in Microbiology and Immunology from East Carolina University School of Medicine (Greenville, NC) where his research focused on T lymphocyte cell signalling, immunosuppression and transformation. Subsequent to his postdoctoral studies at Vanderbilt University (Nashville, TN), which focused on the regulation of gene expression, he then graduated with a MBA in Marketing from Rochester Institute of Technology (Rochester, NY). Dr. Tebbey’s research, development and launch experiences include therapeutic monoclonal antibodies (adalimumab, infliximab and ustekinumab) & antibody-drug conjugates, oncolytics (venetoclax) as well as complex vaccines (conjugated pneumococcal vaccine). Dr. Tebbey’s publications include over 40 peer-reviewed articles that span immunology, immune-mediated and infectious diseases, as well as pharmaceutical publication planning and brand success.
Chief Executive Officer, MedEvoke
Anna Walz is a 25-year veteran in the pharmaceutical industry. She is the CEO of MedEvoke, which she founded in 1999. MedEvoke is dedicated to working with Medical Affairs leaders to drive alignment through development of clear medical strategies that can be globally communicated, measured, and analyzed. This has, for the first time, enabled Medial Affairs to track the impact of internal efforts on the external scientific and digital exchanges. Anna, who often speaks on the topics of medical strategy, launch excellence, impact metrics for medical affairs, female entrepreneurship, and diversity in the biosciences, is also a regular guest-lecturer on the topic of Pharmacology & Drug Marketing at the Rutgers Medical School. In addition to speaking, Anna has a keen interest in her own continuing education and is a graduate of both the Tuck-WBENC Executive Education program and the Entrepreneurial Master’s Program (EMP), a joint collaboration of the Entrepreneurs’ Organization (EO) and the Massachusetts Institute of Technology (MIT).